AccScience Publishing / GTM / Volume 2 / Issue 3 / DOI: 10.36922/gtm.1027
Submit to GTM
Cite this article
93
Download
1129
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Thromboembolism risk in patients diagnosed with EGFR- and ALK-mutant lung adenocarcinoma

Suna Kavurgacı1* ,  Yasemin Söyler1 ,  Pınar Akın Kabalak1 ,  Derya Kızılgöz1 ,  Ülkü Yılmaz1
Show Less
1 Department of Chest Disease, Atatürk Sanatorium Training and Research Hospital, Ankara, Turkey
Global Translational Medicine 2023, 2(3), 1027 https://doi.org/10.36922/gtm.1027
Submitted: 1 June 2023 | Accepted: 30 August 2023 | Published: 12 September 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

In this study, we investigated the incidence of venous thromboembolism (VTE), related risk factors for VTE, and the effect of VTE on overall survival in patients with non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene mutations. The study included patients older than 18 years of age who were diagnosed with histologically proven locally advanced or advanced-stage adenocarcinoma and were followed in our center between January 2014 and December 2019. These patients were divided into two groups: one comprising mutation-positive individuals and the other mutation-negative individuals. We examined factors influencing the occurrence of VTE, assessed the incidence of VTE, and compared the differences in overall survival. Univariate Cox regression analysis revealed that the independent predictors of VTE were the number of metastases (Hazard ratio [HR]: 3.784; 95% confidence interval [CI]: 2.198 – 6.515; P < 0.001) and the presence of EGFR exon 21 mutations (HR: 2.386; 95% CI: 1.276 – 4.462; P = 0.006). However, in multivariate analysis, only the number of comorbidities was associated with an increased risk for VTE (HR: 3.462; 95% CI: 1.977 – 6.060; P < 0.001). It is essential to consider the risk of VTE development in patients with EGFR exon 21 mutation-positive lung adenocarcinoma. Physicians should be vigilant in terms of screening, prophylaxis, and follow-up for underlying VTE in these patients.

Keywords
Pulmonary embolism
Venous thromboembolism
Epidermal growth factor receptor
Survival
Funding
None.
Conflict of interest
All authors declare that they have no conflicts of interest.
References
  1. Shinagare AB, Okajima Y, Oxnard GR, et al., 2012, Unsuspected pulmonary embolism in lung cancer patients: Comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer, 78: 161–166. https://doi.org/10.1016/j.lungcan.2012.08.007

 

  1. Lee AY, 2005, Management of thrombosis in cancer: Primary prevention and secondary prophylaxis. Br J Haematol, 128: 291–302. https://doi.org/10.1111/j.1365-2141.2004.05292.x

 

  1. Blom JW, Doggen CJ, Osanto S, et al., 2005, Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293: 715–722. https://doi.org/10.1001/jama.293.6.715

 

  1. Timp JF, Braekkan SK, Versteeg HH, et al., 2013, Epidemiology of cancer-associated venous thrombosis. Blood, 122: 1712–1723. https://doi.org/10.1182/blood-2013-04-460121

 

  1. Clagett GP, Reisch JS, 1988, Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg, 208: 227–240. https://doi.org/10.1097/00000658-198808000-00016

 

  1. White RH, Zhou H, Romanos PS, 2003, Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost, 90: 446–455. https://doi.org/10.1160/TH03-03-0152

 

  1. Swiniarska J, Zekanowska E, Dancewicz M, et al., 2009, Pneumonectomy due to lung cancer results in a more pronounced activation of coagulation system than lobectomy. Eur J Cardiothorac Surg, 36: 1064–1068. https://doi.org/10.1016/j.ejcts.2009.04.070

 

  1. Yu J, Li A, Laureano M, et al., 2019, Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thromb Res, 184: 16–23. https://doi.org/10.1016/j.thromres.2019.10.004

 

  1. Guan JL, Zhong WZ, An SJ, et al., 2013, KRAS mutation in patients with lung cancer: A predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol, 20: 1381–1388. https://doi.org/10.1245/s10434-012-2754-z

 

  1. Corrales-Rodriguez L, Soulières D, Weng X, et al., 2014, Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study. Thromb Res, 133: 48–51. https://doi.org/10.1016/j.thromres.2013.10.042

 

  1. Verso M, Chiari R, Mosca S, et al., 2015, Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thromb Res, 136: 924–927. https://doi.org/10.1016/j.thromres.2015.09.006

 

  1. Zer A, Moskovitz M, Hwang DM, et al., 2017, ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer, 18: 156–161. https://doi.org/10.1016/j.cllc.2016.10.007

 

  1. Dou F, Zhang Y, Yi J, et al., 2020, Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study. Thromb Res, 186: 36–41. https://doi.org/10.1016/j.thromres.2019.12.009

 

  1. Khorana AA, Vadhan-Raj S, Kuderer NM, et al., 2017, Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: Rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial. Thromb Haemost, 117: 2135–2145. https://doi.org/10.1160/TH17-03-0171

 

  1. Carrier M, Abou-Nassar K, Mallick R, et al., 2019, Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med, 380: 711–719. https://doi.org/10.1056/NEJMoa1814468

 

  1. Key NS, Khorana AA, Kuderer NM, et al., 2020, Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol, 38: 496–520. https://doi.org/10.1200/JCO.19.01461

 

  1. Rami-Porta R, Bolejack V, Giroux DJ, et al., 2014, The IASLC lung cancer staging project: The new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol, 9: 1618–1624. https://doi.org/10.1097/JTO.0000000000000334

 

  1. Varki A, 2007, Trousseau’s syndrome: Multiple definitions and multiple mechanisms. Blood, 110: 1723–1729. https://doi.org/10.1182/blood-2006-10-053736

 

  1. Sawada M, Miyake S, Ohdama S, et al., 1999, Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer, 79: 472–477. https://doi.org/10.1038/sj.bjc.6690073

 

  1. Goldin-Lang P, Tran QV, Fichtner I, 2008, Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep, 20: 123–128. https://doi.org/10.3892/or.20.1.123

 

  1. Minamiya Y, Matsuzaki I, Sageshima M, et al., 2004, Expression of tissue factor mRNA and invasion of blood vessels by tumor cells in non-small cell lung cancer. Surg Today, 34: 1–5. https://doi.org/10.1007/s00595-003-2643-y

 

  1. Belting M, Ahamed J, Ruf W, 2005, Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol, 25: 1545–1550. https://doi.org/10.1161/01.atv.0000171155.05809.bf

 

  1. Sato T, Tsujino I, Ikeda D, et al., 2006, Trousseau’s syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax, 61: 1009–1010. https://doi.org/10.1136/thx.2004.031492

 

  1. Rong Y, Belozerov VE, Tucker-Burden C, et al., 2009, Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/ activator protein-1 transcriptional activity. Cancer Res, 69: 2540–2549. https://doi.org/10.1158/0008-5472.CAN-08-1547

 

  1. Magnus N, Garnier D, Rak J, 2010, Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood, 116: 815–818. https://doi.org/10.1182/blood-2009-10-250639

 

  1. Gary T, 2014, Cancer related venous thromboembolism-prophylaxis and therapy. Vasa, 43: 245–251. https://doi.org/10.1024/0301-1526/a000359

 

  1. Tagalakis V, Levi D, Agulnik JS, et al., 2007, High risk of deep vein thrombosis in patients with non-small cell lung cancer: A cohort study of 493 patients. J Thorac Oncol, 2: 729–734. https://doi.org/10.1097/JTO.0b013e31811ea275

 

  1. Hicks LK, Cheung MC, Ding K, et al., 2009, Venous thromboembolism and nonsmall cell lung cancer: A pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer, 115: 5516–5525. https://doi.org/10.1002/cncr.24596

 

  1. Wang J, Hu B, Li T, et al., 2019, The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism. Ann Transl Med, 7: 724. https://doi.org/10.21037/atm.2019.12.24

 

  1. Dearden S, Stevens J, Wu YL, et al., 2013, Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann Oncol, 24: 2371–2376. https://doi.org/10.1093/annonc/mdt205

 

  1. Qian X, Fu M, Zheng J, et al., 2021, Driver genes associated with the incidence of venous thromboembolism in patients with non-small-Cell lung cancer: A systematic review and meta-analysis. Front Oncol, 11: 680191. https://doi.org/10.3389/fonc.2021.680191

 

  1. Lee YG, Kim I, Lee E, et al., 2014, Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost, 111: 1112–1120. https://doi.org/10.1160/TH13-11-0956

 

  1. Shaw AT, Kim DW, Mehra R, et al., 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370: 1189–1197. https://doi.org/10.1056/NEJMoa1311107

 

  1. Ou SH, Ahn JS, De Petris L, et al., 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol, 34: 661–668. https://doi.org/10.1200/jco.2015.63.9443

 

  1. Carrier M, Khorana AA, Zwicker JI, et al., 2012, Venous thromboembolism in cancer clinical trials: Recommendation for standardized reporting and analysis. J Thromb Haemost, 10: 2599–2601. https://doi.org/10.1111/jth.12028

 

  1. Alexander M, Kirsa S, Wolfe R, et al., 2014, Thromboembolism in lung cancer-an area of urgent unmet need. Lung Cancer, 84: 275–280. https://doi.org/10.1016/j.lungcan.2014.02.009

 

  1. Chew HK, Davies AM, Wun T, et al., 2008, The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost, 6: 601–608. https://doi.org/10.1111/j.1538-7836.2008.02908.x

 

  1. Roselli M, Riondino S, Mariotti S, et al., 2014, Clinical models and biochemical predictors of VTE in lung cancer. Cancer Metastasis Rev, 33: 771–789. https://doi.org/10.1007/s10555-014-9500-x

 

  1. Ay C, Ünal UK, 2016, Epidemiology and risk factors for venous thromboembolism in lung cancer. Curr Opin Oncol, 28: 145–149. https://doi.org/10.1097/CCO.0000000000000262

 

  1. Kadlec J, Skrickova ZM, Merta Z, et al., 2014, The incidence and predictors of thromboembolic events in patients with lung cancer. ScientificWorldJournal, 2014: 125706. https://doi.org/10.1155/2014/125706

 

  1. Demirci NY, Turay UY, Ylmaz A, et al., 2011, Vascular events in lung cancer. Asian Pac J Cancer Prev, 12: 2685–2687.

 

  1. Pedersen LM, Milman N, 1996, Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J, 9: 1826–1830. https://doi.org/10.1183/09031936.96.09091826

 

  1. Fei X, Wang H, Yuan W, et al., 2017, Tissue factor pathway inhibitor-1 is a valuable marker for the prediction of deep venous thrombosis and tumor metastasis in patients with lung cancer. Biomed Res Int, 2017: 8983763. https://doi.org/10.1155/2017/8983763

 

  1. Shiina Y, Nakajima T, Yamamoto T, et al., 2019, The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer. PLoS One, 14: e0222050. https://doi.org/10.1371/journal.pone.0222050
Share
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept